Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
This syndrome is characterized by progressive spastic paraplegia and distal muscle wasting.
Features include common findings: Babinski sign, Atrophy of the spinal cord, Overactive reflexes (hyperreflexia), and Spastic paraplegia and others; and sometimes findings: Shrinkage of the cerebellum (cerebellar atrophy), Ataxia, and Gait ataxia. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 9 | Difficulty walking (gait disturbance), Babinski sign, Progressive spastic paraplegia |
Muscles | 4 | Distal lower limb muscle weakness, Atrophy of the spinal cord, Shrinkage of the cerebellum (cerebellar atrophy) |
Arms and legs | 3 | Distal lower limb muscle weakness, Lower limb spasticity, Generalized limb muscle atrophy |
In all affected individuals reported to date, features of the PNPLA6 disorder are evident in the first two decades of life [, , , , , , ]. The initial findings include one or several of the following features: gait disturbance, visual impairment due to chorioretinal dystrophy or atrophy, anterior hypopituitarism, delayed puberty/primary amenorrhea. Gait disturbance may precede visual impairment or anterior hypopituitarism; or alternatively, gait disturbance may follow visual impairment or hypopituitarism up to 35 years later . Although the combination of the three most common findings (gait disturbance, visual impairment, and delayed puberty/primary amenorrhea) is highly indicative of an underlying PNPLA6 disorder, no single feature is specific or obligatory. Some of these features can occur in certain combinations, presenting in partly distinct/partly overlapping clusters on the phenotypic continuum of the PNPLA6 disorders . • Boucher-Neuhuser syndrome (BNS). Cerebellar ataxia, chorioretinal dystrophy, and hypogonadotropic hypogonadism ; high predictive value (75%) for an underlying PNPLA6 disorder • Gordon Holmes syndrome (GHS). Cerebellar ataxia, hypogonadotropic hypogonadism, and (to a variable degree) brisk reflexes • Oliver-McFarlane syndrome (OMCS). Trichomegaly, chorioretinal dystrophy, and congenital or childhood hypopituitarism • Laurence-Moon syndrome (LMS). Cerebellar ataxia, chorioretinal dystrophy, peripheral neuropathy, spastic paraplegia and congenital or childhood hypopituitarism. One family diagnosed with Laurence-Moon syndrome has been reported to have biallelic pathogenic variants in PNPLA6 . Several other people with the same phenotypic cluster and biallelic pathogenic variants in PNPLA6 have been reported and described as having "spastic Boucher-Neuhuser syndrome," demonstrating the continuum of PNPLA6- associated phenotypic clusters. • Spastic paraplegia type 39 (SPG39). Upper motor neuron involvement and peripheral neuropathy, and in some cases reduced cognitive functioning and/or cerebellar ataxia • Severe retinal dystrophy with atrophy associated with autism, reported in one child with biallelic pathogenic variants in PNPLA6 . The child had been previously given a diagnosis of Leber congenital amaurosis (LCA). Given the age of the affected individual, it is possible that further features of one of the above clinical diagnoses could develop with time. See Leber Congenital Amaurosis/ Early-Onset Severe Retinal Dystrophy Overview. Table 2. PNPLA6 Disorders: Comparison of Phenotypic Clusters by Select Features Phenotypic Feature | PNPLA6 Disorder
BNS | GHS | OMCS | LMS | SPG39 |
|---|---|---|---|---|
Cerebellar ataxia | + | + | + | ± Peripheral neuropathy |
± Chorioretinal dystrophy | + | — | — | — |
+ | + | — | — | — |
Hypogonadotropic hypogonadism |
Source: GeneReviews — "PNPLA6 Disorders"
PNPLA6 function has not been fully characterized.
Hereditary spastic paraplegia 39 is associated with mutations in the PNPLA6 gene on chromosome 19.
No consensus clinical diagnostic criteria for PNPLA6 disorders have been published.
A PNPLA6 disorder should be suspected in individuals with a combination of the following clinical features, neuroimaging, and family history (rather than any of these features in isolation).
Clinical features
Source: GeneReviews — "PNPLA6 Disorders"
Disorders with Ataxia Table 3. Disorders with Ataxia in the Differential Diagnosis of PNPLA6 Disorders
Gene(s) | DiffDx Disorder | MOI | Clinical Features of DiffDx Disorder | Distinguishing Features |
|---|---|---|---|---|
ANGPTL3APOBMTTP1 | Abetalipoproteinemia familial hypobetalipoproteinemia (OMIM 615558, 605019) | AR | RP, progressive ataxia, steatorrhea, demyelinating neuropathy, dystonia, extrapyramidal signs, spastic paraparesis (rare)2 | PNPLA6 disorders w/retinopathy typically incl anterior pituitary hormone deficiency. ATXN7 |
Genetic testing for PNPLA6 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary spastic paraplegia 39 has been reported in the published literature.
No approved treatments are currently available for hereditary spastic paraplegia 39. The disease remains an area of unmet medical need.
No clinical practice guidelines for PNPLA6 disorder have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with a PNPLA6 disorder, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with a PNPLA6 Disorder
System/Concern | Evaluation | Comment |
|---|---|---|
Ataxia | By neurologist for cerebellar motor dysfunction: gait postural ataxia, dysmetria, dysdiadochokinesis, tremor, dysarthria, nystagmus, saccades smooth pursuit | Use standardized scale to establish baseline for ataxia (SARA).1 LMN involvement (motor sensory |
neuropathy) | Weakness, amyotrophy, fasciculations, sensory involvement | Nerve conduction studies EMG to determine presence extent of peripheral neuropathy UMN involvement |
(spasticity) | Spasticity, Babinski signs, hyperreflexia | Use standardized scale to establish baseline for spasticity (SPRS).2 Neuro- |
imaging | MRI of the cerebrum (incl pituitary), cerebellum, spinal cord (incl thoracic cord) | To establish extent of atrophy in the different brain regions exclude secondary causes of clinical features |
Musculoskeletal/ADL |
Source: GeneReviews — "PNPLA6 Disorders"
Avoid the following:
Alcohol
Obesity
Inactive, sedentary lifestyle
Exposure to medications or chemicals that exacerbate neuropathy. See the Charcot-Marie-Tooth Association website (pdf) for an up-to-date list of medications that are potentially toxic to persons with CMT or a related neuropathy.
Source: GeneReviews — "PNPLA6 Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "PNPLA6 Disorders"
View trials for hereditary spastic paraplegia 39
Affected individuals require periodic multidisciplinary reevaluations to assess disease progression and modify treatment strategies. Note that the frequency of recommended surveillance is at the discretion of treating specialists (usually annually or as symptoms change or as medication needs change).
Table 6.
Recommended Surveillance for Individuals with a PNPLA6 Disorder
System/Concern | Evaluation
| • Neurologic assessment for progression of ataxia; UMN or LMN signs
Monitor ataxia progression w/standardized scale (SARA).1
Physiatry, OT/PT assessment of mobility, self-help skills as they relate to ataxia, spasticity, weakness
| Assess aspiration risk feeding methods.
Weight / Nutritional
status | • Monitor BMI.
Consult nutritionist.
Assess need for high-calorie supplementation.
| Assess need for alternative communication method or speech therapy.
| Per treating urologist
| Per treating developmental pediatrician
| Per treating ophthalmologist low vision clinic
Hypogonadotropic
hypogonadism | Per treating endocrinologist
Hypothyroidism
Growth hormone
deficiency
| Assess needs of affected person care provider(s).
OT/PT = occupational therapy / physical therapy; SARA = Scale for the Assessment and Rating of Ataxia
1.
Source: GeneReviews — "PNPLA6 Disorders"
Phenotype severity distribution: 7 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hereditary spastic paraplegia 39.
18 publications have been identified in PubMed for hereditary spastic paraplegia 39. Research spans Case Report / Case Series (33%), Diagnostic / Biomarker (28%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 33% |
Testing and diagnosis research | 5 | 28% |
Research summaries | 2 | 11% |
Disease patterns and progression | 2 | 11% |
Other research | 1 | 6% |
Clinical study results | 1 | 6% |
Laboratory research | 1 | 6% |
Mimori M (2026). [PMID: 41813186](https://pubmed.ncbi.nlm.nih.gov/41813186/). *Rinsho Shinkeigaku*. [Case Report / Case Series]
Alawadhi A (2026). [PMID: 42147656](https://pubmed.ncbi.nlm.nih.gov/42147656/). *Cureus*. [Case Report / Case Series]
Toyoda N (2026). [PMID: 41503587](https://pubmed.ncbi.nlm.nih.gov/41503587/). *eNeurologicalSci*. [Case Report / Case Series]
Lin PY (2026). [PMID: 40518753](https://pubmed.ncbi.nlm.nih.gov/40518753/). *Acta Neurol Taiwan*. [Epidemiology / Natural History]
Erhardt C (2026). [PMID: 41774218](https://pubmed.ncbi.nlm.nih.gov/41774218/). *Metab Brain Dis*. [Epidemiology / Natural History]
Yu HP (2025). [PMID: 40375209](https://pubmed.ncbi.nlm.nih.gov/40375209/). *BMC Neurol*. [Diagnostic / Biomarker]
Rudaks LI (2025). [PMID: 40007153](https://pubmed.ncbi.nlm.nih.gov/40007153/). *Ann Clin Transl Neurol*. [Diagnostic / Biomarker]
Ivanova EA (2025). [PMID: 41303565](https://pubmed.ncbi.nlm.nih.gov/41303565/). *Int J Mol Sci*. [Basic Science / Preclinical]
Lessard LE (2025). [PMID: 41222985](https://pubmed.ncbi.nlm.nih.gov/41222985/). *J Neuromuscul Dis*. [Case Report / Case Series]
Özdemir TR (2025). [PMID: 40445718](https://pubmed.ncbi.nlm.nih.gov/40445718/). *Ann Indian Acad Neurol*. [Diagnostic / Biomarker]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 3:25 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
+
+ |
— |
— |
Congenital/childhood anterior hypopituitarism | + | + | Trichomegaly | BNS = Boucher-Neuhuser syndrome; GHS = PNPLA6 Gordon Holmes syndrome; LMS = PNPLA6 Laurence-Moon syndrome; OMCS = Oliver-McFarlane syndrome; SPG39 = spastic paraplegia type 39 Note: The clusters in this table do not constitute distinct phenotypes, as they may overlap in many affected individuals. |
SCA7 | AD | Progressive cerebellar ataxia (incl dysarthria dysphagia) a cone-rod retinal dystrophy w/progressive central visual loss blindness in affected adults3 | PNPLA6 disorders present w/widespread rod-cone or cone-rod retinal degeneration can incl hypogonadism. MT-ATP6 MT-ND6 | — |
MT-TV | NARP (See mtDNA-Associated Leigh Syndrome Spectrum.) | Mat | Childhood-onset disease most often characterized by proximal neurogenic muscle weakness w/sensory neuropathy, ataxia, learning difficulties, pigmentary retinopathy | PNPLA6 disorders w/retinopathy typically incl anterior pituitary hormone deficiency. |
OTUD4RNF2164 | RNF216/OTUD4 ataxia-hypogonadism | AR | Ataxia w/hypogonadism dementia | PNPLA6 disorders do not typically incl dementia. PEX7 PHYH |
Refsum disease | AR | Anosmia (a universal finding) early-onset RP w/variable combinations of chronic polyneuropathy, deafness, cerebellar ataxia, ichthyosis; cardiac conduction disorders are common. | Hearing loss has not been reported in PNPLA6 disorders. POLR3A POLR3B POLR1C | — |
POLR3 leukodystrophy | AR | Hypomyelinating leukodystrophy w/neurologic (cerebellar, extrapyramidal, pyramidal, cognitive) non-neurologic (dental, endocrine, ocular) features | PNPLA6 disorders are not assoc w/dental abnormalities or leukodystrophy. | — |
SIL1 | Marinesco-Sjgren syndrome (MSS) | AR | Cerebellar ataxia w/cerebellar atrophy, early-onset cataracts, mild-to-severe ID, hypotonia, muscle weakness, hypergonadotropic hypogonadism; after age 7 yrs. | — |
Source: GeneReviews — "PNPLA6 Disorders"
OT/PT/rehab specialist
To assess gross motor fine motor skills, gait, ambulation, need for adaptive devices, ongoing need for PT OT Feeding |
Speech | For those w/dysarthria: speech-language eval | Consider referral to speech language pathologist. |
Bladder dysfunction | Hx of spastic bladder symptoms: urgency, frequency, difficulty voiding | Referral to urologist; consider urodynamic eval. |
Cognitive dysfunction | Neuropsychological investigation | Incl assessment of IQ, attention span, visuospatial abilities, recall |
Chorioretinal dystrophy | By ophthalmologist | Best corrected visual acuity, visual field testing, fundoscopy, retinal imaging, OCT Anterior pituitary deficiency |
Genetic counseling | By genetics professionals3 | To inform affected persons their families re nature, MOI, implications of a PNPLA6 disorder to facilitate medical personal decision making Family support resources |